ES2958412T3 - Cerdulatinib para el tratamiento de tumores malignos de linfocitos B - Google Patents

Cerdulatinib para el tratamiento de tumores malignos de linfocitos B Download PDF

Info

Publication number
ES2958412T3
ES2958412T3 ES16804177T ES16804177T ES2958412T3 ES 2958412 T3 ES2958412 T3 ES 2958412T3 ES 16804177 T ES16804177 T ES 16804177T ES 16804177 T ES16804177 T ES 16804177T ES 2958412 T3 ES2958412 T3 ES 2958412T3
Authority
ES
Spain
Prior art keywords
cerdulatinib
pharmaceutically acceptable
acceptable salt
patient
mutation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES16804177T
Other languages
English (en)
Spanish (es)
Inventor
Anjali Pandey
Gregory Coffey
Janet Leeds
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alexion Pharmaceuticals Inc
Original Assignee
Alexion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharmaceuticals Inc filed Critical Alexion Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2958412T3 publication Critical patent/ES2958412T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES16804177T 2015-05-29 2016-05-27 Cerdulatinib para el tratamiento de tumores malignos de linfocitos B Active ES2958412T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562168530P 2015-05-29 2015-05-29
US201562263582P 2015-12-04 2015-12-04
PCT/US2016/034861 WO2016196385A1 (en) 2015-05-29 2016-05-27 Cerdulatinib for the treatment of b-cell malignancies

Publications (1)

Publication Number Publication Date
ES2958412T3 true ES2958412T3 (es) 2024-02-08

Family

ID=57441822

Family Applications (1)

Application Number Title Priority Date Filing Date
ES16804177T Active ES2958412T3 (es) 2015-05-29 2016-05-27 Cerdulatinib para el tratamiento de tumores malignos de linfocitos B

Country Status (9)

Country Link
US (2) US20180147203A1 (cg-RX-API-DMAC7.html)
EP (1) EP3302485B1 (cg-RX-API-DMAC7.html)
JP (2) JP7258462B2 (cg-RX-API-DMAC7.html)
KR (1) KR102613106B1 (cg-RX-API-DMAC7.html)
CN (1) CN107683139A (cg-RX-API-DMAC7.html)
AU (1) AU2016270658B2 (cg-RX-API-DMAC7.html)
CA (1) CA2987324C (cg-RX-API-DMAC7.html)
ES (1) ES2958412T3 (cg-RX-API-DMAC7.html)
WO (1) WO2016196385A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2913119T3 (es) 2015-08-12 2022-05-31 Portola Pharm Inc Cerdulatinib para tratar mieloma
EP3383396B1 (en) 2015-12-04 2023-07-12 Alexion Pharmaceuticals, Inc. Cerdulatinib and venetoclax for treating non-hodgkin's lymphoma
US20180065317A1 (en) 2016-09-06 2018-03-08 Cc3D Llc Additive manufacturing system having in-situ fiber splicing
WO2018189566A1 (en) * 2017-04-10 2018-10-18 Dorian Bevec Use of a chemical compound as a therapeutic agent
KR20210003789A (ko) * 2018-05-04 2021-01-12 포톨라 파마슈티컬스, 인코포레이티드 림프종을 치료하는 방법
US10851087B2 (en) 2018-05-04 2020-12-01 Portola Pharmaceuticals, Inc. Synthesis of cerdulatinib
WO2019213606A2 (en) 2018-05-04 2019-11-07 Portola Pharmaceuticals, Inc. Solid forms of cerdulatinib
CN108743947B (zh) * 2018-07-04 2020-12-15 复旦大学附属肿瘤医院 一种治疗b细胞淋巴瘤的药物组合物
WO2021242614A1 (en) * 2020-05-26 2021-12-02 Alexion Pharmaceuticals, Inc. Circulating b cell subpopulations in indolent b cell lymphoma
EP4189080A4 (en) * 2020-07-26 2025-01-08 ASC Therapeutics Inc. CAS NUCLEASE VARIANTS

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60255756A (ja) 1984-06-01 1985-12-17 Ikeda Mohandou:Kk アミノアルキルフエノキシ誘導体
WO1995032963A1 (en) 1994-06-01 1995-12-07 Yoshitomi Pharmaceutical Industries, Ltd. Thienylazole compound and thienotriazolodiazepine compound
ATE401312T1 (de) 1997-12-15 2008-08-15 Astellas Pharma Inc Pyrimidin-5-carboxamid-derivate
WO2003037352A1 (en) 2001-11-02 2003-05-08 Pfizer Products Inc. 1-phenyl-5-n-heterocyclyl-pyrazoles as cyclooxygenase inhibitors for the treatment of inflammation associated disorders
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
ES2373226T3 (es) 2002-06-28 2012-02-01 Astellas Pharma Inc. Derivado de diaminopirimidincarboxamida.
WO2008009458A1 (en) 2006-07-21 2008-01-24 Novartis Ag 2, 4 -di (arylaminio) -pyrimidine-5-carboxamide compounds as jak kinases inhibitors
CA2723205C (en) 2008-04-16 2017-03-14 Portola Pharmaceuticals, Inc. 2,6-diamino-pyrimidin-5-yl-carboxamides as syk or jak kinase inhibitors
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
WO2010129802A1 (en) 2009-05-06 2010-11-11 Portola Pharmaceuticals, Inc. Inhibitors of jak
WO2012045020A1 (en) 2010-09-30 2012-04-05 Portola Pharmaceuticals, Inc. Combinations of 4-(cyclopropylamino)-2-(4-(4-(ethylsulfonyl)piperazin-1-yl)phenylamino)pyrimidine-5-carboxamide and fludarabine
WO2013023119A1 (en) * 2011-08-10 2013-02-14 Novartis Pharma Ag JAK P13K/mTOR COMBINATION THERAPY
US20150368394A1 (en) * 2012-06-27 2015-12-24 Novomer, Inc. Catalysts and methods for polyester production
HK1206073A1 (en) * 2012-07-24 2015-12-31 药品循环有限责任公司 Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
WO2014058921A2 (en) 2012-10-08 2014-04-17 Portola Pharmaceuticals, Inc. Substituted pyrimidinyl kinase inhibitors
SG11201503459SA (en) 2012-11-02 2015-06-29 Pharmacyclics Inc Tec family kinase inhibitor adjuvant therapy
CN105282602A (zh) * 2014-07-07 2016-01-27 乐视致新电子科技(天津)有限公司 数据处理方法、装置及移动终端设备
EP3191098A4 (en) 2014-09-12 2018-04-25 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
ES2913119T3 (es) 2015-08-12 2022-05-31 Portola Pharm Inc Cerdulatinib para tratar mieloma
EP3383396B1 (en) 2015-12-04 2023-07-12 Alexion Pharmaceuticals, Inc. Cerdulatinib and venetoclax for treating non-hodgkin's lymphoma

Also Published As

Publication number Publication date
KR102613106B1 (ko) 2023-12-12
AU2016270658B2 (en) 2021-08-12
JP7258462B2 (ja) 2023-04-17
AU2016270658A1 (en) 2018-01-04
CN107683139A (zh) 2018-02-09
EP3302485A4 (en) 2019-02-27
US20220096471A1 (en) 2022-03-31
US12350269B2 (en) 2025-07-08
CA2987324C (en) 2023-08-22
KR20180011210A (ko) 2018-01-31
JP2021152076A (ja) 2021-09-30
EP3302485A1 (en) 2018-04-11
JP2018520117A (ja) 2018-07-26
CA2987324A1 (en) 2016-12-08
WO2016196385A1 (en) 2016-12-08
EP3302485B1 (en) 2023-07-12
US20180147203A1 (en) 2018-05-31

Similar Documents

Publication Publication Date Title
US12350269B2 (en) Cerdulatinib for the treatment of b-cell malignancies
US11446300B2 (en) Cerdulatinib for treating hematological cancers
ES2863996T3 (es) Terapia de combinación para el tratamiento del cáncer
BR112019017851A2 (pt) método para tratar câncer em um indivíduo que precisa do mesmo, método para identificar um indivíduo que tem um câncer como um candidato para o tratamento com um antagonista de smarca2, método para identificar uma célula cancerosa como sensível ao tratamento com um antagonista de smarca2, antagonista de smarca2 para uso no tratamento de câncer em um indivíduo que precisa do mesmo, antagonista de smarca2 para uso como um medicamento no tratamento de câncer em um indivíduo que precisa do mesmo e uso do antagonista de smarca2 na fabricação de um medicamento no tratamento de câncer em um indivíduo que precisa do mesmo
CN102427814A (zh) 激酶蛋白结合抑制剂
JP2019511204A (ja) コパンリシブバイオマーカー
JP2019512003A (ja) コパンリシブバイオマーカー
BR112020022430A2 (pt) métodos para tratamento de linfoma
Zhang et al. Bioevaluation of a dual PI3K/HDAC inhibitor for the treatment of diffuse large B-cell lymphoma
HK1253804A1 (en) Cerdulatinib for the treatment of b-cell malignancies
HK1253804B (en) Cerdulatinib for the treatment of b-cell malignancies
HK1262118B (en) Cerdulatinib and venetoclax for treating non-hodgkin's lymphoma
HK1262118A1 (en) Cerdulatinib and venetoclax for treating non-hodgkin's lymphoma
HK40000537A (en) Copanlisib biomarkers